Pfizer Inc. $PFE Shares Sold by Seizert Capital Partners LLC

Key Points

• Seizert Capital Partners LLC reduced its stake in Pfizer by 71.3% in Q4, selling 102,174 shares and retaining 41,123 shares valued at $1.024 million per its latest 13F filing.
• Pfizer declared a quarterly dividend of $0.43 (annualized $1.72) for a yield of 6.5%, though the payout ratio is high at 126.47%, raising questions about dividend sustainability.
• Recent positive catalysts include FDA approval of VEPPANU for ESR1‑mutated advanced breast cancer, analyst optimism around the obesity and oncology pipeline, and a Q4 earnings beat ($0.66 vs. $0.57 consensus), supporting near‑term sentiment.

Seizert Capital Partners LLC decreased its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 71.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 41,123 shares of the biopharmaceutical company's stock after selling 102,174 shares during the period. Seizert Capital Partners LLC's holdings in Pfizer were worth $1,024,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Horizon Financial Services LLC lifted its stake in shares of Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 645 shares during the period. YANKCOM Partnership acquired a new stake in shares of Pfizer in the fourth quarter valued at about $28,000. Grey Fox Wealth Advisors LLC acquired a new position in Pfizer during the third quarter worth about $29,000. True Wealth Design LLC raised its position in Pfizer by 302.5% during the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company's stock worth $33,000 after acquiring an additional 974 shares during the last quarter. Finally, Darwin Wealth Management LLC acquired a new position in Pfizer during the second quarter worth about $32,000. Institutional investors and hedge funds own 68.36% of the company's stock.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA approval: Pfizer and Arvinas won FDA approval for VEPPANU (vepdegestrant), a first-of-its-kind therapy for ESR1‑mutated advanced breast cancer — a commercial and pipeline catalyst that can expand oncology revenue and investor expectations. Read More.
• Positive Sentiment: Analyst support: Guggenheim reaffirmed a Buy and a $36 price target ahead of Q1, highlighting upcoming pipeline catalysts and raising expectations for revenue and guidance. Read More.
• Positive Sentiment: Analysts bullish on pipeline: Q1 previews emphasize a robust non‑COVID portfolio and investor focus on obesity and oncology programs — key drivers that could lift guidance and sentiment if management commentary is constructive. Read More.
• Positive Sentiment: Relative positioning vs. peers: Coverage argues Pfizer is a post‑COVID winner versus Moderna thanks to diversification and a push into obesity drugs — narrative supports defensive, income‑oriented investor interest. Read More.
• Neutral Sentiment: Dividend/income focus: Several pieces highlight Pfizer’s attractive yield and option strategies for income generation ahead of earnings — this sustains interest from income investors but raises sensitivity to dividend safety and payout guidance. Read More.
• Neutral Sentiment: Q1 earnings watch: Preview and “what to look for” pieces flag EPS/revenue estimates, obesity program updates and guidance commentary as the immediate drivers; results/guidance will likely dictate short‑term direction. Read More.
• Neutral Sentiment: Macro headwind: Major indexes dipped amid rising oil and geopolitical tension — broader market weakness can pressure cyclicals and large caps like Pfizer even if company‑specific news is positive. Read More.
• Negative Sentiment: Media skepticism on yield/valuation: Commentators including Jim Cramer warned that Pfizer’s yield isn’t compelling enough relative to bonds and questioned upside, which can deter income/value buyers. Read More.
• Negative Sentiment: Valuation/long‑term skepticism: Opinion pieces label the stock “priced like dead money,” underscoring investor concern about limited capital‑gains potential despite high yield — a headwind for growth‑oriented flows. Read More.

Pfizer Stock Performance

NYSE:PFE opened at $26.31 on Tuesday. The firm has a 50 day simple moving average of $27.17 and a 200-day simple moving average of $26.11. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The firm has a market cap of $149.61 billion, a PE ratio of 19.35 and a beta of 0.35. Pfizer Inc. has a 1-year low of $21.97 and a 1-year high of $28.75.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating analysts' consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company's revenue was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.63 earnings per share. On average, equities analysts expect that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.5%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer's payout ratio is currently 126.47%.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Weiss Ratings restated a "hold (c-)" rating on shares of Pfizer in a research report on Thursday, January 22nd. Daiwa Securities Group cut shares of Pfizer from an "outperform" rating to a "neutral" rating and set a $27.00 target price for the company. in a research report on Thursday, February 12th. Argus upgraded shares of Pfizer from a "hold" rating to a "buy" rating and set a $35.00 target price for the company in a research report on Monday, March 2nd. CICC Research assumed coverage on shares of Pfizer in a research report on Thursday, April 16th. They set an "outperform" rating and a $33.00 target price for the company. Finally, BMO Capital Markets restated an "outperform" rating and set a $30.00 target price on shares of Pfizer in a research report on Monday, March 9th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $28.74.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.